erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
.

.
but shocking figures uncovered by labour yesterday show some patients are suffering agonising waits of as many as 541 days to begin treatment. https://drbryanpwalsh.com/Reckleben-grandma-of-Jarvie-from-Crumpler?Adeyemosi=108
�now we know the astonishing truth that some patients are waiting a year or more just to get treatment. it�s simply not good enough.�.
.